Update on Chronic Hepatitis B

Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide and over 1 million die annually of HBV-related chronic liver disease. The prolonged immunologic response to HBV infection leads to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) in up...

Full description

Saved in:
Bibliographic Details
Published in:Journal for nurse practitioners 2010-09, Vol.6 (8), p.631-639
Main Authors: Rustgi, Vinod, Carriero, Damaris, Bachtold, Michelle, Zeldin, Gillian
Format: Article
Language:English
Subjects:
Adolescents
Antiviral drugs
chronic HBV infection
Chronic liver diseases
cirrhosis
Health initiatives
Hepatitis
Hepatitis B
hepatocellular carcinoma
Hispanic Americans
HIV
Human immunodeficiency virus
Infection
Infections
interferon
Liver
Liver cirrhosis
Preventive programmes
Sexually transmitted diseases
STD
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide and over 1 million die annually of HBV-related chronic liver disease. The prolonged immunologic response to HBV infection leads to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) in up to 40% of patients. The implementation of mass immunization programs has dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries, but there remains a large number who were infected with HBV before such programs. A variety of host, viral, and external factors influence HBV disease progression and the risk of chronic infection. Six drugs are currently FDA-approved for the treatment of chronic HBV infection. While novel antiviral drugs have improved the management of cirrhosis, strategies to prevent and treat HCC remain inadequate.
ISSN:1555-4155
1878-058X
DOI:10.1016/j.nurpra.2010.01.004